{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T21:13:30Z","timestamp":1792790010428,"version":"4.5.0"},"reference-count":73,"publisher":"MDPI AG","issue":"10","license":[{"start":{"date-parts":[[2022,9,21]],"date-time":"2022-09-21T00:00:00Z","timestamp":1663718400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000774","name":"Defense Threat Reduction Agency (DTRA)","doi-asserted-by":"publisher","award":["MCDC-18-06-17-001"],"award-info":[{"award-number":["MCDC-18-06-17-001"]}],"id":[{"id":"10.13039\/100000774","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000774","name":"Defense Threat Reduction Agency (DTRA)","doi-asserted-by":"publisher","award":["UC7AI094660"],"award-info":[{"award-number":["UC7AI094660"]}],"id":[{"id":"10.13039\/100000774","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000774","name":"Defense Threat Reduction Agency (DTRA)","doi-asserted-by":"publisher","award":["W15QKN-16-9-1002"],"award-info":[{"award-number":["W15QKN-16-9-1002"]}],"id":[{"id":"10.13039\/100000774","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"Department of Health and Human Services, National Institutes of Health","doi-asserted-by":"publisher","award":["MCDC-18-06-17-001"],"award-info":[{"award-number":["MCDC-18-06-17-001"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"Department of Health and Human Services, National Institutes of Health","doi-asserted-by":"publisher","award":["UC7AI094660"],"award-info":[{"award-number":["UC7AI094660"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"Department of Health and Human Services, National Institutes of Health","doi-asserted-by":"publisher","award":["W15QKN-16-9-1002"],"award-info":[{"award-number":["W15QKN-16-9-1002"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"name":"U.S. Government","award":["MCDC-18-06-17-001"],"award-info":[{"award-number":["MCDC-18-06-17-001"]}]},{"name":"U.S. Government","award":["UC7AI094660"],"award-info":[{"award-number":["UC7AI094660"]}]},{"name":"U.S. Government","award":["W15QKN-16-9-1002"],"award-info":[{"award-number":["W15QKN-16-9-1002"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccines"],"abstract":"<jats:p>Vaccines are needed to disrupt or prevent continued outbreaks of filoviruses in humans across Western and Central Africa, including outbreaks of Marburg virus (MARV). As part of a filovirus vaccine product development plan, it is important to investigate dose response early in preclinical development to identify the dose range that may be optimal for safety, immunogenicity, and efficacy, and perhaps demonstrate that using lower doses is feasible, which will improve product access. To determine the efficacious dose range for a manufacturing-ready live recombinant vesicular stomatitis virus vaccine vector (rVSV\u2206G-MARV-GP) encoding the MARV glycoprotein (GP), a dose-range study was conducted in cynomolgus macaques. Results showed that a single intramuscular injection with as little as 200 plaque-forming units (PFUs) was 100% efficacious against lethality and prevented development of viremia and clinical pathologies associated with MARV Angola infection. Across the vaccine doses tested, there was nearly a 2000-fold range of anti-MARV glycoprotein (GP) serum IgG titers with seroconversion detectable even at the lowest doses. Virus-neutralizing serum antibodies also were detected in animals vaccinated with the higher vaccine doses indicating that vaccination induced functional antibodies, but that the assay was a less sensitive indicator of seroconversion. Collectively, the data indicates that a relatively wide range of anti-GP serum IgG titers are observed in animals that are protected from disease implying that seroconversion is positively associated with efficacy, but that more extensive immunologic analyses on samples collected from our study as well as future preclinical studies will be valuable in identifying additional immune responses correlated with protection that can serve as markers to monitor in human trials needed to generate data that can support vaccine licensure in the future.<\/jats:p>","DOI":"10.3390\/vaccines10101582","type":"journal-article","created":{"date-parts":[[2022,9,23]],"date-time":"2022-09-23T04:07:07Z","timestamp":1663906027000},"page":"1582","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Nonhuman Primates Are Protected against Marburg Virus Disease by Vaccination with a Vesicular Stomatitis Virus Vector-Based Vaccine Prepared under Conditions to Allow Advancement to Human Clinical Trials"],"prefix":"10.3390","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5211-6502","authenticated-orcid":false,"given":"Christopher L.","family":"Cooper","sequence":"first","affiliation":[{"name":"IAVI, New York, NY 10004, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5436-1993","authenticated-orcid":false,"given":"Gavin","family":"Morrow","sequence":"additional","affiliation":[{"name":"IAVI, New York, NY 10004, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maoli","family":"Yuan","sequence":"additional","affiliation":[{"name":"IAVI, New York, NY 10004, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0177-6583","authenticated-orcid":false,"given":"John W.","family":"Coleman","sequence":"additional","affiliation":[{"name":"IAVI, New York, NY 10004, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fuxiang","family":"Hou","sequence":"additional","affiliation":[{"name":"IAVI, New York, NY 10004, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucia","family":"Reiserova","sequence":"additional","affiliation":[{"name":"IAVI, New York, NY 10004, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shui L.","family":"Li","sequence":"additional","affiliation":[{"name":"IAVI, New York, NY 10004, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denise","family":"Wagner","sequence":"additional","affiliation":[{"name":"IAVI, New York, NY 10004, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexei","family":"Carpov","sequence":"additional","affiliation":[{"name":"IAVI, New York, NY 10004, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivia","family":"Wallace-Selman","sequence":"additional","affiliation":[{"name":"IAVI, New York, NY 10004, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0502-9297","authenticated-orcid":false,"given":"Kristie","family":"Valentin","sequence":"additional","affiliation":[{"name":"IAVI, New York, NY 10004, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yesle","family":"Choi","sequence":"additional","affiliation":[{"name":"IAVI, New York, NY 10004, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron","family":"Wilson","sequence":"additional","affiliation":[{"name":"IAVI, New York, NY 10004, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Kilianski","sequence":"additional","affiliation":[{"name":"IAVI, New York, NY 10004, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eddy","family":"Sayeed","sequence":"additional","affiliation":[{"name":"IAVI, New York, NY 10004, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krystle N.","family":"Agans","sequence":"additional","affiliation":[{"name":"Galveston National Laboratory, University of Texas Medical Branch, Galveston, TX 77555, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viktoriya","family":"Borisevich","sequence":"additional","affiliation":[{"name":"Galveston National Laboratory, University of Texas Medical Branch, Galveston, TX 77555, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert W.","family":"Cross","sequence":"additional","affiliation":[{"name":"Galveston National Laboratory, University of Texas Medical Branch, Galveston, TX 77555, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0858-1877","authenticated-orcid":false,"given":"Thomas W.","family":"Geisbert","sequence":"additional","affiliation":[{"name":"Galveston National Laboratory, University of Texas Medical Branch, Galveston, TX 77555, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark B.","family":"Feinberg","sequence":"additional","affiliation":[{"name":"IAVI, New York, NY 10004, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Swati B.","family":"Gupta","sequence":"additional","affiliation":[{"name":"IAVI, New York, NY 10004, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher L.","family":"Parks","sequence":"additional","affiliation":[{"name":"IAVI, New York, NY 10004, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,9,21]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"103958","DOI":"10.1016\/j.amsu.2022.103958","article-title":"Ebola virus outbreak returns to the Democratic Republic of Congo: An urgent rising concern","volume":"79","author":"Sun","year":"2022","journal-title":"Ann. Med. Surg."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1038\/s41586-021-03901-9","article-title":"Resurgence of Ebola virus in 2021 in Guinea suggests a new paradigm for outbreaks","volume":"597","author":"Keita","year":"2021","journal-title":"Nature"},{"key":"ref_3","unstructured":"WHO (2022, July 08). Ebola Virus Disease\u2014Democratic Republic of the Congo. Available online: https:\/\/www.who.int\/emergencies\/disease-outbreak-news\/item\/2022-DON377."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1056\/NEJMp1807691","article-title":"Outbreaks in a Rapidly Changing Central Africa\u2014Lessons from Ebola","volume":"379","author":"Munster","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1093\/trstmh\/trv024","article-title":"Mapping the zoonotic niche of Marburg virus disease in Africa","volume":"109","author":"Pigott","year":"2015","journal-title":"Trans. R. Soc. Trop. Med. Hyg."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"2528","DOI":"10.1056\/NEJMc2120183","article-title":"Detection of Marburg Virus Disease in Guinea","volume":"386","author":"Koundouno","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_7","unstructured":"WHO (2022, July 12). Ghana Reports First-Ever Suspected Cases of Marburg Virus Disease. Available online: https:\/\/www.afro.who.int\/countries\/ghana\/news\/ghana-reports-first-ever-suspected-cases-marburg-virus-disease."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1038\/s41586-022-04788-w","article-title":"Climate change increases cross-species viral transmission risk","volume":"607","author":"Carlson","year":"2022","journal-title":"Nature"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.2217\/fvl.11.79","article-title":"Clinical aspects of Marburg hemorrhagic fever","volume":"6","author":"Mehedi","year":"2011","journal-title":"Future Virol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"e59","DOI":"10.1093\/milmed\/usx004","article-title":"Beyond the Dirty Dozen: A Proposed Methodology for Assessing Future Bioweapon Threats","volume":"183","author":"Cieslak","year":"2018","journal-title":"Mil. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1001\/jama.287.18.2391","article-title":"Hemorrhagic fever viruses as biological weapons: Medical and public health management","volume":"287","author":"Borio","year":"2002","journal-title":"JAMA"},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Tell, J.G., Coller, B.G., Dubey, S.A., Jenal, U., Lapps, W., Wang, L., and Wolf, J. (2020). Environmental Risk Assessment for rVSVDeltaG-ZEBOV-GP, a Genetically Modified Live Vaccine for Ebola Virus Disease. Vaccines, 8.","DOI":"10.3390\/vaccines8040779"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"2855","DOI":"10.1080\/21645515.2020.1741313","article-title":"Lessons learned from Zaire ebolavirus to help address urgent needs for vaccines against Sudan ebolavirus and Marburg virus","volume":"16","author":"Wolfe","year":"2020","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Wolf, J., Jannat, R., Dubey, S., Troth, S., Onorato, M.T., Coller, B.A., Hanson, M.E., and Simon, J.K. (2021). Development of Pandemic Vaccines: ERVEBO Case Study. Vaccines, 9.","DOI":"10.3390\/vaccines9030190"},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Santoro, F., Donato, A., Lucchesi, S., Sorgi, S., Gerlini, A., Haks, M.C., Ottenhoff, T.H.M., Gonzalez-Dias, P., VSV-EBOVAC Consortium, and VSV-EBOPLUS Consortium (2021). Human Transcriptomic Response to the VSV-Vectored Ebola Vaccine. Vaccines, 9.","DOI":"10.3390\/vaccines9020067"},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Pinski, A.N., and Messaoudi, I. (2020). To B or Not to B: Mechanisms of Protection Conferred by rVSV-EBOV-GP and the Roles of Innate and Adaptive Immunity. Microorganisms, 8.","DOI":"10.3390\/microorganisms8101473"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"599568","DOI":"10.3389\/fimmu.2020.599568","article-title":"Ebolavirus: Comparison of Survivor Immunology and Animal Models in the Search for a Correlate of Protection","volume":"11","author":"Longet","year":"2020","journal-title":"Front. Immunol"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"e348","DOI":"10.1016\/S1473-3099(21)00006-2","article-title":"Antibody responses to filovirus infections in humans: Protective or not?","volume":"21","author":"Ilinykh","year":"2021","journal-title":"Lancet Infect. Dis."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1146\/annurev-micro-090817-062414","article-title":"Ebola: Lessons on Vaccine Development","volume":"72","author":"Feldmann","year":"2018","journal-title":"Annu. Rev. Microbiol"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"e70","DOI":"10.1016\/S2666-5247(20)30198-1","article-title":"Estimation of the correlates of protection of the rVSV\u0394G-ZEBOV-GP Zaire ebolavirus vaccine: A post-hoc analysis of data from phase 2\/3 clinical trials","volume":"2","author":"Grais","year":"2021","journal-title":"Lancet Microbe"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1038\/s41591-019-0607-z","article-title":"A glimpse into immune responses evolving against Ebola virus","volume":"25","author":"Saphire","year":"2019","journal-title":"Nat. Med."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1038\/s41590-018-0233-9","article-title":"Antibody-mediated protection against Ebola virus","volume":"19","author":"Saphire","year":"2018","journal-title":"Nat. Immunol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"3071","DOI":"10.3389\/fimmu.2018.03071","article-title":"Protection Against Marburg Virus Using a Recombinant VSV-Vaccine Depends on T and B Cell Activation","volume":"9","author":"Marzi","year":"2018","journal-title":"Front. Immunol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"774026","DOI":"10.3389\/fimmu.2021.774026","article-title":"Single Dose of a VSV-Based Vaccine Rapidly Protects Macaques From Marburg Virus Disease","volume":"12","author":"Marzi","year":"2021","journal-title":"Front. Immunol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"3071","DOI":"10.1038\/s41598-020-59976-3","article-title":"Immune correlates of postexposure vaccine protection against Marburg virus","volume":"10","author":"Woolsey","year":"2020","journal-title":"Sci. Rep."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Woolsey, C., Cross, R.W., Agans, K.N., Borisevich, V., Deer, D.J., Geisbert, J.B., Gerardi, C., Latham, T.E., Fenton, K.A., and Egan, M.A. (2022). A highly attenuated Vesiculovax vaccine rapidly protects nonhuman primates against lethal Marburg virus challenge. PLoS Negl. Trop. Dis., 16.","DOI":"10.1101\/2022.01.22.477345"},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Mire, C.E., Geisbert, J.B., Agans, K.N., Satterfield, B.A., Versteeg, K.M., Fritz, E.A., Feldmann, H., Hensley, L.E., and Geisbert, T.W. (2014). Durability of a vesicular stomatitis virus-based marburg virus vaccine in nonhuman primates. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0094355"},{"key":"ref_28","unstructured":"U.S. Food and Drug Administration (2015). Product Development under the Animal Rule Guidance for Industry."},{"key":"ref_29","unstructured":"U.S. Food and Drug Administration (2022, July 12). Accelerated Approval Program, Available online: https:\/\/www.fda.gov\/drugs\/information-health-care-professionals-drugs\/accelerated-approval-program."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Finch, C.L., Martinez, C., Leffel, E., Skiadopoulos, M.H., Hacker, A., Mwesigwa, B., Maiga, D., Mugisa, I., Munkwase, G., and Rustomjee, R. (2022). Vaccine Licensure in the Absence of Human Efficacy Data. Vaccines, 10.","DOI":"10.3390\/vaccines10030368"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1832","DOI":"10.1056\/NEJMra1901594","article-title":"Ebola","volume":"382","author":"Feldmann","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.vaccine.2020.11.042","article-title":"Systematic review of Marburg virus vaccine nonhuman primate studies and human clinical trials","volume":"39","author":"Dulin","year":"2021","journal-title":"Vaccine"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"S1075","DOI":"10.1093\/infdis\/jir349","article-title":"Recombinant vesicular stomatitis virus-based vaccines against Ebola and Marburg virus infections","volume":"204","author":"Geisbert","year":"2011","journal-title":"J. Infect. Dis."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"2269","DOI":"10.1080\/21645515.2019.1649532","article-title":"Recombinant vesicular stomatitis virus vector vaccines for WHO blueprint priority pathogens","volume":"15","author":"Fathi","year":"2019","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_35","unstructured":"WHO (2022, July 08). A WHO Strategic Agenda for Filovirus Research and Monitoring (AFIRM)\u2014Roadmap Meeting. Available online: https:\/\/www.who.int\/news-room\/events\/detail\/2022\/03\/30\/default-calendar\/save-the-date-a-who-strategic-agenda-for-filovirus-research-and-monitoring-(afirm)---roadmap-meeting."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1177\/17407745211073594","article-title":"The ring vaccination trial design for the estimation of vaccine efficacy and effectiveness during infectious disease outbreaks","volume":"19","author":"Dean","year":"2022","journal-title":"Clin. Trials"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"6894","DOI":"10.1016\/j.vaccine.2008.09.082","article-title":"Vesicular stomatitis virus-based vaccines protect nonhuman primates against aerosol challenge with Ebola and Marburg viruses","volume":"26","author":"Geisbert","year":"2008","journal-title":"Vaccine"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"7296","DOI":"10.1128\/JVI.00561-09","article-title":"Single-injection vaccine protects nonhuman primates against infection with marburg virus and three species of ebola virus","volume":"83","author":"Geisbert","year":"2009","journal-title":"J. Virol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.3201\/eid1607.100159","article-title":"Postexposure treatment of Marburg virus infection","volume":"16","author":"Geisbert","year":"2010","journal-title":"Emerg. Infect. Dis."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1038\/nm1258","article-title":"Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses","volume":"11","author":"Jones","year":"2005","journal-title":"Nat. Med."},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Mire, C.E., Miller, A.D., Carville, A., Westmoreland, S.V., Geisbert, J.B., Mansfield, K.G., Feldmann, H., Hensley, L.E., and Geisbert, T.W. (2012). Recombinant vesicular stomatitis virus vaccine vectors expressing filovirus glycoproteins lack neurovirulence in nonhuman primates. PLoS Negl. Trop. Dis., 6.","DOI":"10.1371\/journal.pntd.0001567"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"S91","DOI":"10.1093\/infdis\/jiv284","article-title":"Considerations in the Use of Nonhuman Primate Models of Ebola Virus and Marburg Virus Infection","volume":"212","author":"Geisbert","year":"2015","journal-title":"J. Infect. Dis."},{"key":"ref_43","first-page":"241","article-title":"A Comparison of the Pathogenesis of Marburg Virus Disease in Humans and Nonhuman Primates and Evaluation of the Suitability of These Animal Models for Predicting Clinical Efficacy under the \u2018Animal Rule\u2019","volume":"65","author":"Glaze","year":"2015","journal-title":"Comp. Med."},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Blair, P.W., Keshtkar-Jahromi, M., Psoter, K.J., Reisler, R.B., Warren, T.K., Johnston, S.C., Goff, A.J., Downey, L.G., Bavari, S., and Cardile, A.P. (2018). Virulence of Marburg Virus Angola Compared to Mt. Elgon (Musoke) in Macaques: A Pooled Survival Analysis. Viruses, 10.","DOI":"10.3390\/v10110658"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"5458","DOI":"10.1128\/JVI.78.10.5458-5465.2004","article-title":"Properties of replication-competent vesicular stomatitis virus vectors expressing glycoproteins of filoviruses and arenaviruses","volume":"78","author":"Garbutt","year":"2004","journal-title":"J. Virol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"9659","DOI":"10.1128\/JVI.00959-06","article-title":"Cross-protection against Marburg virus strains by using a live, attenuated recombinant vaccine","volume":"80","author":"Geisbert","year":"2006","journal-title":"J. Virol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"104203","DOI":"10.1016\/j.ebiom.2022.104203","article-title":"Preclinical immunogenicity and efficacy of a candidate COVID-19 vaccine based on a vesicular stomatitis virus-SARS-CoV-2 chimera","volume":"82","author":"Espeseth","year":"2022","journal-title":"EBioMedicine"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1093\/infdis\/jiw500","article-title":"First-in-Human Evaluation of the Safety and Immunogenicity of an Intranasally Administered Replication-Competent Sendai Virus-Vectored HIV Type 1 Gag Vaccine: Induction of Potent T-Cell or Antibody Responses in Prime-Boost Regimens","volume":"215","author":"Nyombayire","year":"2017","journal-title":"J. Infect. Dis."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.jviromet.2009.11.023","article-title":"Refined methods for propagating vesicular stomatitis virus vectors that are defective for G protein expression","volume":"164","author":"Witko","year":"2010","journal-title":"J. Virol. Methods"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.jviromet.2006.02.006","article-title":"An efficient helper-virus-free method for rescue of recombinant paramyxoviruses and rhadoviruses from a cell line suitable for vaccine development","volume":"135","author":"Witko","year":"2006","journal-title":"J. Virol. Methods"},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Rabinovich, S., Powell, R.L., Lindsay, R.W., Yuan, M., Carpov, A., Wilson, A., Lopez, M., Coleman, J.W., Wagner, D., and Sharma, P. (2014). A novel, live-attenuated vesicular stomatitis virus vector displaying conformationally intact, functional HIV-1 envelope trimers that elicits potent cellular and humoral responses in mice. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0106597"},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"Geisbert, T.W., Jones, S., Fritz, E.A., Shurtleff, A.C., Geisbert, J.B., Liebscher, R., Grolla, A., Stroher, U., Fernando, L., and Daddario, K.M. (2005). Development of a new vaccine for the prevention of Lassa fever. PLoS Med., 2.","DOI":"10.1371\/journal.pmed.0020183"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"S582","DOI":"10.1093\/infdis\/jiy293","article-title":"Postexposure Efficacy of Recombinant Vesicular Stomatitis Virus Vectors Against High and Low Doses of Marburg Virus Variant Angola in Nonhuman Primates","volume":"218","author":"Woolsey","year":"2018","journal-title":"J. Infect. Dis."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1016\/S0140-6736(06)68546-2","article-title":"Postexposure protection against Marburg haemorrhagic fever with recombinant vesicular stomatitis virus vectors in non-human primates: An efficacy assessment","volume":"367","author":"Geisbert","year":"2006","journal-title":"Lancet"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"6937","DOI":"10.1128\/JVI.73.8.6937-6945.1999","article-title":"Replication-competent rhabdoviruses with human immunodeficiency virus type 1 coats and green fluorescent protein: Entry by a pH-independent pathway","volume":"73","author":"Boritz","year":"1999","journal-title":"J. Virol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"2318","DOI":"10.1128\/jvi.70.4.2318-2323.1996","article-title":"The minimal conserved transcription stop-start signal promotes stable expression of a foreign gene in vesicular stomatitis virus","volume":"70","author":"Schnell","year":"1996","journal-title":"J. Virol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"4477","DOI":"10.1073\/pnas.92.10.4477","article-title":"Recombinant vesicular stomatitis viruses from DNA","volume":"92","author":"Lawson","year":"1995","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"7432","DOI":"10.1038\/s41598-021-86688-z","article-title":"Flow virometry for process monitoring of live virus vaccines-lessons learned from ERVEBO","volume":"11","author":"Ricci","year":"2021","journal-title":"Sci. Rep."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.ebiom.2019.09.055","article-title":"Single low-dose VSV-EBOV vaccination protects cynomolgus macaques from lethal Ebola challenge","volume":"49","author":"Marzi","year":"2019","journal-title":"EBioMedicine"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jviromet.2018.01.003","article-title":"High degree of correlation between Ebola virus BSL-4 neutralization assays and pseudotyped VSV BSL-2 fluorescence reduction neutralization test","volume":"254","author":"Konduru","year":"2018","journal-title":"J. Virol. Methods"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1016\/j.vaccine.2016.11.083","article-title":"Comparison of platform technologies for assaying antibody to Ebola virus","volume":"35","author":"Wilkinson","year":"2017","journal-title":"Vaccine"},{"key":"ref_62","doi-asserted-by":"crossref","unstructured":"Niemuth, N.A., Fallacara, D., Triplett, C.A., Tamrakar, S.M., Rajbhandari, A., Florence, C., Ward, L., Griffiths, A., Carrion, R., and Goez-Gazi, Y. (2021). Natural history of disease in cynomolgus monkeys exposed to Ebola virus Kikwit strain demonstrates the reliability of this non-human primate model for Ebola virus disease. PLoS ONE, 16.","DOI":"10.1371\/journal.pone.0252874"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1080\/22221751.2022.2086072","article-title":"Natural history of Sudan ebolavirus infection in rhesus and cynomolgus macaques","volume":"11","author":"Woolsey","year":"2022","journal-title":"Emerg. Microbes Infect."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1016\/S1473-3099(15)00154-1","article-title":"The effect of dose on the safety and immunogenicity of the VSV Ebola candidate vaccine: A randomised double-blind, placebo-controlled phase 1\/2 trial","volume":"15","author":"Huttner","year":"2015","journal-title":"Lancet. Infect. Dis."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"E819","DOI":"10.1503\/cmaj.170074","article-title":"Assessing the safety and immunogenicity of recombinant vesicular stomatitis virus Ebola vaccine in healthy adults: A randomized clinical trial","volume":"189","author":"ElSherif","year":"2017","journal-title":"CMAJ"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1016\/S1473-3099(17)30313-4","article-title":"Safety and immunogenicity of the rVSVG-ZEBOV-GP Ebola virus vaccine candidate in healthy adults: A phase 1b randomised, multicentre, double-blind, placebo-controlled, dose-response study","volume":"17","author":"Heppner","year":"2017","journal-title":"Lancet Infect. Dis."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1056\/NEJMoa1502924","article-title":"Phase 1 Trials of rVSV Ebola Vaccine in Africa and Europe","volume":"374","author":"Agnandji","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1038\/s41591-019-0602-4","article-title":"Polyclonal and convergent antibody response to Ebola virus vaccine rVSV-ZEBOV","volume":"25","author":"Ehrhardt","year":"2019","journal-title":"Nat. Med."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1016\/j.chom.2020.03.025","article-title":"Non-neutralizing Antibodies from a Marburg Infection Survivor Mediate Protection by Fc-Effector Functions and by Enhancing Efficacy of Other Antibodies","volume":"27","author":"Ilinykh","year":"2020","journal-title":"Cell Host Microbe"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"eaai8711","DOI":"10.1126\/scitranslmed.aai8711","article-title":"Therapeutic treatment of Marburg and Ravn virus infection in nonhuman primates with a human monoclonal antibody","volume":"9","author":"Mire","year":"2017","journal-title":"Sci. Transl. Med."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1038\/s41467-018-08040-w","article-title":"Post-exposure immunotherapy for two ebolaviruses and Marburg virus in nonhuman primates","volume":"10","author":"Brannan","year":"2019","journal-title":"Nat. Commun."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"4465","DOI":"10.1016\/j.vaccine.2017.05.097","article-title":"Clinical development of a recombinant Ebola vaccine in the midst of an unprecedented epidemic","volume":"35","author":"Coller","year":"2017","journal-title":"Vaccine"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1080\/14760584.2018.1527692","article-title":"Unprecedented pace and partnerships: The story of and lessons learned from one Ebola vaccine program","volume":"17","author":"Gupta","year":"2018","journal-title":"Expert Rev. Vaccines"}],"container-title":["Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-393X\/10\/10\/1582\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T00:36:49Z","timestamp":1760143009000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-393X\/10\/10\/1582"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,21]]},"references-count":73,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2022,10]]}},"alternative-id":["vaccines10101582"],"URL":"https:\/\/doi.org\/10.3390\/vaccines10101582","relation":{},"ISSN":["2076-393X"],"issn-type":[{"value":"2076-393X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,21]]}}}